Association between the Use of Diuretics and Size Reduction in Pediatric Atrial Septal Defect

Jue Seong Lee, MD, Gi Beom Kim, MD, PhD, Won Jung Lee, Seok Hyun Song, Hyo Soon An, MD, PhD, Sang Yun Lee, MD, PhD, Mi Kyung Song, MD, Hye Won Kwon, MD, and Eun Jung Bae, MD, PhD

1Department of Pediatrics, Korea University College of Medicine and Korea University Medical Center, Seoul, Korea
2Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Children's Hospital, Seoul, Korea
3Seoul National University College of Medicine, Seoul, Korea

AUTHOR’S SUMMARY

The effect of diuretics on ASD size reduction remains unclear. In pediatric patients with a large secundum ASD (≥10 mm), diuretic administration seemed to be associated with changes in ASD size. There seemed to be little possibility of ASD size reduction other than the aortic rim. The patients receiving diuretics may have a lower possibility to undergo surgical closure. The diuretics administration may be associated with the use of smaller ASD devices.

ABSTRACT

Background and Objectives: While diuretics are sometimes used in atrial septal defect (ASD) treatment, their effect on ASD size reduction remains unclear. We aimed to evaluate the efficacy of diuretics in ASD size reduction in pediatric patients.

Methods: We retrospectively reviewed the medical records of patients with secundum ASD (size ≥10 mm), between 2005 and 2019. Patients were divided into two groups based on the diuretic administration.

Results: Of the 73 enrolled patients, 40 received diuretics. The initial age at ASD diagnosis (2.8±1.7 vs. 2.5±2.0 years, p=0.526) and follow-up duration (22.3±11.4 vs. 18.7±13.2 months, p=0.224) were not significantly different between the groups. The ASD diameter at the initial diagnosis (13.7±2.0 vs. 13.5±3.4 mm, p=0.761) and the indexed ASD diameter (25.5±5.9 vs. 26.9±10.3 mm/m², p=0.493) were also not significantly different between two groups. The ASD diameter significantly increased in the non-diuretic group during follow-up (0.0±2.9 vs. +2.6±2.0 mm, p<0.001). The indexed ASD diameter significantly decreased in the diuretic group during follow-up (−5.7±6.5 vs. +0.2±3.9 mm/m², p<0.001). In the linear mixed model analysis, diuretic use was associated with ASD diameter decrease (p<0.001) and indexed ASD diameter reduction (p<0.001) over time. Device closure was more frequently performed in the diuretic (75.0%) than in the non-diuretic group (39.4%).

Conclusions: Patients receiving diuretics are less likely to undergo surgery. The diuretics administration may be associated with the use of smaller ASD devices for transcatheter treatment through ASD size reduction.
INTRODUCTION

Atrial septal defect (ASD) is among the most commonly reported congenital heart diseases (CHDs), accounting for about 10% of all CHDs in children,\(^1\) with secundum ASD comprising approximately 80% of the ASDs.\(^2\)

Some patients with a large ASD remain asymptomatic until adulthood\(^\text{2}\); however, if left untreated, symptoms such as dyspnea, arrhythmia, reduced functional capacity, right heart failure, respiratory infections, and stroke may present through right ventricle (RV) volume overload and pulmonary overflow.\(^\text{2}\)\(^\text{3}\)

Although both transcatheter and surgical closures yield excellent short and long-term ASD treatment outcomes,\(^4\) several studies have reported the superiority of transcatheter closure to surgery in terms of hospitalization duration, costs, and rates of treatment-related complications and infections.\(^5\)\(^\text{6}\)

As a part of ASD treatment, diuretics are occasionally administered to reduce the rate of RV volume overload for the control of heart failure-related symptoms\(^6\); however, the effect of diuretics on ASD size change remains unclear. This study aimed to evaluate the efficacy of diuretics in ASD size reduction by comparing patients who received and did not receive diuretic treatment, and their outcomes.

METHODS

Ethical statement

This study was approved by the Institutional Review Board of Seoul National University Hospital (IRB No. 2003-191-1112) and the need for consent was waived owing to the retrospective study design.

Patient characteristics

We retrospectively reviewed the medical records of pediatric patients diagnosed with a large secundum ASD (size ≥10 mm), as observed on echocardiography, at the Seoul National University Children’s Hospital between 2005 and 2019. Patients with other concomitant CHDs, such as a ventricular septal defect or patent ductus arteriosus, and those aged ≥10 years were excluded. Patients were divided into two groups based on their diuretic reception status. Patients who received diuretics and were followed-up for a sufficient duration (approximately 2 years) were assigned to the diuretic group. If parents wanted device closure to be performed after the patient had grown a little more while not requiring immediate ASD closure, diuretics were given for the purpose of RV volume unloading. Age-matched patients who were not treated with diuretics for a sufficient duration during study period were assigned to the non-diuretic group. Data regarding the patients' gestational age, weight, height, genetic defect, clinical symptoms, and the use of diuretics and treatment, including transcatheter and surgical closures, were collected.

Keywords: Atrial septal defect; Diuretics; Pediatrics; Device; Surgery
Echocardiographic measurement of atrial septal defect

Of the ASD images recorded from various angles, the largest measured ASD size was selected, and for data consistency, the ASD size was re-evaluated from the ASD images measured at the same view wherever possible. Since the patient’s somatic growth occurred during the administration of the diuretics, the indexed ASD diameter was also evaluated to compare the ASD size over the patient’s body surface area (BSA) for the correction of body size differences. From the available images, aortic, superior vena cava (SVC), inferior vena cava (IVC), posterior, and mitral rim measurements were performed. Rim deficiency was defined as a rim size <5 mm. The presence of a floppy interatrial septum, multiple ASDs, and other heart anomalies were evaluated. All patients’ echocardiography findings, as obtained during follow-up, were investigated for serial changes in the ASD size. To decrease the degree of inter-observer variability, the ASD size was remeasured by a cardiologist who was blinded to the patients’ information, including their diuretic administration status; these measurements were averaged with the previously recorded ASD size.

Outcome measurements

The primary outcome was the effect of diuretics on ASD size reduction and treatment outcomes. The secondary outcome was the identification of the risk factors associated with a lack of ASD size reduction and those related to the need for surgical closure despite diuretic use. Owing to concerns pertaining to growth retardation related to diuretic administration, the percentiles of the patients’ height and body weight were evaluated before initiating diuretics and after the reception of follow-up echocardiography. To determine the sex and age-specific percentiles for height and body weight, Korea Centers for Disease Control and Prevention data were used.

Statistical analysis

Statistical analyses were performed using SPSS version 25 (IBM Corp., Armonk, NY, USA). Continuous variables are expressed as mean ± standard deviation or median (interquartile range: 25\textsuperscript{th} to 75\textsuperscript{th} percentile) and categorical variables as numbers and percentages. Continuous variables were compared using either Student’s t-test or Mann–Whitney U tests and categorical variables by employing \(\chi^2\) or Fisher’s exact tests. Linear mixed model analysis was performed for the identification of meaningful factors associated with ASD diameter and indexed ASD diameter change. A p value of <0.05 was considered statistically significant.

RESULTS

Baseline characteristics

Seventy-three patients with an ASD diameter ≥10 mm were enrolled in this study. Diuretics were administered in 40 of them. The patients’ baseline characteristics are shown in Table 1. The initial age at ASD diagnosis was not significantly different between the diuretic and non-diuretic groups (2.8±1.7 vs. 2.5±2.0 years, respectively, p=0.526). The follow-up duration was also not significantly different between two groups (22.3±11.4 vs. 18.7±13.2 months, respectively, p=0.224). Patients in the diuretic group were prescribed, on average, a starting dose of 0.77±0.19 mg/kg/day furosemide and 0.81±0.19 mg/kg/day spironolactone and the diuretic dosage rose with increasing body weight. The definite treatment age was higher in the diuretic group (5.3±1.4 vs. 4.0±1.8 years, p=0.003).
Changes in atrial septal defect size over time

Echocardiography was usually performed every 6 months or 1-year and the changes in the ASD size were investigated until just before transcatheter or surgical ASD closure. Data regarding the ASD size changes are presented in Table 1. The ASD diameter at initial diagnosis (13.7±3.8 vs. 13.5±3.4 mm, p=0.761) and the indexed ASD diameter (25.5±5.9 vs. 26.9±10.3 mm/m², p=0.493) were not significantly different between two groups. At the last follow-up, the ASD diameter (13.7±3.8 vs. 16.1±4.5 mm, p=0.016) and the indexed ASD diameter (19.7±5.7 vs. 27.1±12.2 mm/m², p=0.003) were significantly smaller in the diuretic group. During the follow-up, the non-diuretic group (2.6±2.0 mm) showed significantly increased ASD diameter change compared with the diuretic group (0.0±2.9, p<0.001). The indexed ASD diameter significantly decreased in the diuretic group during follow-up (−5.7±6.5 vs 0.2±3.9 mm/m², respectively, p<0.001) (Table 1).

We used linear mixed model analysis to investigate the degree of ASD size changes with echocardiography examinations adjusted for follow-up duration in both groups. Both the ASD and indexed ASD diameter changes showed significant differences over time in both groups; the patients who received diuretics showed a significant ASD size-decreasing tendency compared to the non-diuretic group (ASD diameter, p for interaction<0.001; indexed ASD diameter, p for interaction<0.001; Figure 1).

### Table 1. Baseline characteristics and ASD size changes

| Characteristics                  | Overall (n=73) | Diuretics use group (n=40) | Non-diuretic group (n=33) | p value |
|----------------------------------|----------------|---------------------------|----------------------------|---------|
| Age at diagnosis (years)         | 2.7±1.8        | 2.8±1.7                   | 2.5±2.0                    | 0.526   |
| Initial BSA (m²)                 | 0.55±0.15      | 0.56±0.12                 | 0.55±0.18                  | 0.826   |
| Male                             | 26 (35.6)      | 13 (32.5)                 | 13 (39.4)                  | 0.540   |
| Follow-up duration (months)      | 20.7±12.3      | 22.3±14.1                 | 18.7±13.2                  | 0.224   |
| ASD closure age (years)          | 4.5±1.8        | 5.3±1.4                   | 4.0±1.8                    | 0.003   |
| Initial diuretics dose           |                |                           |                            |         |
| Furosemide (mg/kg)               | 0.77±0.19      |                           |                            |         |
| Spironolactone (mg/kg)           | 0.81±0.19      |                           |                            |         |
| Gene mutation                    | 3 (4.1)        | 1 (2.5)                   | 2 (6.1)                    | 0.586   |
| Preterm (<37 weeks)              | 3 (4.1)        | 2 (5.0)                   | 1 (3.0)                    | 1.000   |
| ASD characteristics              |                |                           |                            |         |
| Initial ASD D (mm)               | 13.6±2.7       | 13.7±2.0                  | 13.5±3.4                   | 0.761   |
| Initial indexed ASD D (mm/m²)    | 261±8.2        | 25.5±5.9                  | 26.9±10.3                  | 0.493   |
| Last ASD D (mm)                  | 14.8±4.3       | 13.7±3.8                  | 16.1±4.5                   | 0.016   |
| Last indexed ASD D (mm/m²)       | 23.1±9.9       | 19.7±5.7                  | 27.1±12.2                  | 0.003   |
| ASD D change (mm) during follow-up| 1.2±2.8        | 0.0±2.9                   | 2.6±2.0                    | <0.001  |
| Indexed ASD D change during follow-up | −3.0±6.2   | −5.7±6.5                  | 0.2±3.9                    | <0.001  |
| Deficient rims                   |                |                           |                            |         |
| Aortic                           | 71 (97.3)      | 39 (97.5)                 | 32 (97)                    | 1.000   |
| Posterior                        | 23 (31.5)      | 14 (35.0)                 | 9 (27.3)                   | 0.614   |
| SVC rim                          | 7 (9.6)        | 3 (7.5)                   | 4 (12.1)                   | 0.694   |
| IVC rim                          | 17 (23.3)      | 3 (7.5)                   | 14 (42.4)                  | 0.001   |
| Mitral rim                       | 4 (5.5)        | 3 (7.5)                   | 1 (3.0)                    | 0.622   |
| Floppy interatrial septum        | 10 (13.7)      | 3 (7.5)                   | 7 (21.2)                   | 0.169   |
| Multiple ASD                     | 3 (4.1)        | 2 (5.0)                   | 1 (3.0)                    | 1.000   |
| Other heart anomaly              | 11 (15.1)      | 6 (15.0)                  | 5 (15.2)                   | 1.000   |

Values are mean ± standard deviation or number (%).

ASD = atrial septal defect; ASD D = atrial septal defect diameter; BSA = body surface area; IVC = inferior vena cava; SVC = superior vena cava.
We investigated the distribution patterns in the two groups based on the ASD diameter change status and divided the patients into the decreased, stationary (within ±1 mm), and increased groups. In the diuretic group, the ASD diameter was decreased, stationary, and increased in 20.0%, 45.0%, and 35.0% of the patients, respectively. In the non-diuretic group, none of the patients showed ASD diameter decrease, and it was stationary and increased in 18.2% and 81.8% of the patients, respectively (Figure 2).

Factors affecting atrial septal defect size change

Table 2 presents the results of linear mixed model analyses of ASD diameter change and indexed ASD diameter change. The use of diuretics was the significant factor independently associated with ASD diameter decrease during follow-up (p for interaction<0.001). Initial ASD diameter (p<0.001) and IVC rim deficiency (p=0.002) also showed significance for ASD diameter change. In the analysis for indexed ASD diameter change (mm/m²), the use of diuretics was the significant factor associated with reductions in the indexed ASD diameter during follow-up (p for interaction<0.001). In addition, IVC rim deficiency was a significant factor for indexed ASD diameter increase (p=0.001). Initial ASD diameter (p=0.039) and initial indexed ASD diameter (p<0.001) also showed significance for indexed ASD diameter change.

We assumed that the use of diuretics would be related to the difference in right atrium (RA)/RV dimensions, and to investigate this, we measured the tricuspid valve (TV) annulus diameter in a 4-chamber view on echocardiogram. And the z-score values of the TV annulus diameter were compared in the two groups. In the diuretic group, the TV annulus diameters of 38 patients were measured. The mean initial tricuspid annulus z-score was 0.8±0.5, and the last TV annulus z-score was 0.6±0.5. On the other hand, in the non-diuretic group, the
TV annulus diameters of 27 patients were measured. The mean initial TV annulus z-score was 0.7±0.6, and the last TV annulus z-score was 0.8±0.5. The TV annulus z-score change showed a significant difference over time between the two groups. (p for interaction=0.019, Figure 3).

Table 2. Linear mixed model analysis for ASD diameter change and indexed ASD diameter change

| ASD size change | Estimate | 95% CI     | p value |
|-----------------|----------|------------|---------|
| ASD diameter change (mm) |          |            |         |
| Intercept       | −0.591   | −4.866 to 3.684 | 0.784 |
| Age at diagnosis (years) | 0.142    | −0.419 to 0.704 | 0.614 |
| Male            | −0.320   | −1.054 to 0.415 | 0.388 |
| Initial BSA (m²) | −3.036   | −10.945 to 4.874 | 0.446 |
| Initial ASD D (mm) | 1.167     | 0.921 to 1.412 | <0.001 |
| Initial indexed ASD D (mm/m²) | −0.069    | −0.183 to 0.046 | 0.334 |
| Follow-up duration (months) | −0.006   | −0.037 to 0.024 | 0.684 |
| Number of echocardiograms | 1.292    | 0.906 to 1.679 | <0.001 |
| Diuretic use    | 1.539    | 0.284 to 2.795 | 0.017 |
| Diuretic use×Number of echocardiograms | −1.301   | −1.785 to −0.817 | <0.001 |
| Deficient IVC rim | 1.699    | 0.642 to 2.757 | 0.002 |
| Floppy interatrial septum | −0.495   | −1.154 to 0.534 | 0.349 |

| Indexed ASD diameter change (mm/m²) |          |            |         |
| Intercept       | 6.203    | −1.903 to 4.309 | 0.132 |
| Age at diagnosis (years) | 0.633     | −0.432 to 1.698 | 0.240 |
| Male            | −0.805   | −2.200 to 0.589 | 0.254 |
| Initial BSA (m²) | −11.885  | −26.900 to 3.126 | 0.119 |
| Initial ASD D (mm) | 0.491    | 0.025 to 0.957 | 0.039 |
| Initial indexed ASD D (mm/m²) | 0.706    | 0.489 to 0.923 | <0.001 |
| Follow-up duration (months) | −0.039   | −0.097 to 0.019 | 0.187 |
| Number of echocardiograms | −0.041   | −0.075 to 0.677 | 0.891 |
| Diuretic use    | 2.918    | 0.565 to 5.270 | 0.015 |
| Diuretic use×Number of echocardiograms | −2.606   | −3.506 to −1.706 | <0.001 |
| Deficient IVC rim | 3.449    | 1.442 to 5.455 | 0.002 |
| Floppy interatrial septum | −1.108   | −3.101 to 0.885 | 0.271 |

ASD = atrial septal defect; ASD D = atrial septal defect diameter; BSA = body surface area; IVC = inferior vena cava.
Furthermore, we investigated the characteristics of the three subgroups according to the ASD size change in the diuretic group. None of the clinical features including age, initial ASD size, and follow-up duration showed significant differences between the three groups (Table 3). Posterior rim deficiency was the only factor that showed significant differences between the groups (p=0.006). The decreased ASD size subgroup had no posterior rim deficiency; the stationary and the increased ASD size subgroups included 35.7% (n=5) and 64.3% (n=9) of the patients with posterior rim deficiency, respectively.

**Growth-rate difference between the diuretic and non-diuretic groups**

Table 4 shows the average body weight and height percentiles both in the diuretic and non-diuretic groups. While the initial weight and height percentiles were not significantly different, they tended to be higher in the non-diuretic group. Moreover, both the weight and height percentiles at the last measurement were not significantly different. Depending on the usage of diuretics, both the weight and height percentile changes over time did not show any

---

**Table 3. Characteristics of each group according to ASD size change in the diuretic group**

| Characteristics                        | Decreased group (n=8) | Stationary group (n=18) | Increased group (n=14) | p value |
|----------------------------------------|-----------------------|-------------------------|------------------------|---------|
| Age at diagnosis (years)               | 1.8 [0.8 to 5.0]      | 2.5 [1.5 to 3.5]        | 2.9 [2.0 to 4.0]       | 0.808   |
| Initial BSA (m$^2$)                    | 0.52 [0.4 to 0.75]    | 0.54 [0.5 to 0.61]      | 0.56 [0.52 to 0.61]    | 0.798   |
| Initial weight percentile (%)          | 50 [17.5 to 68.8]     | 20 [3 to 75]            | 20 [3 to 75]           | 0.602   |
| Initial height percentile (%)          | 62.5 [25 to 75]       | 50 [25 to 85]           | 25 [8.3 to 75]         | 0.262   |
| Male/female                            | 2 (15.4)/6 (22.2)     | 7 (53.8)/11 (40.7)      | 4 (30.6)/10 (37.0)     | 0.747   |
| Initial ASD D (mm)                     | 13.5 [12.8 to 14.2]   | 13.3 [12.1 to 14.7]     | 14.5 [12.0 to 15.7]    | 0.763   |
| Initial indexed ASD D (mm/m$^2$)       | 24.3 [18.6 to 33.6]   | 24.8 [22.0 to 28.5]     | 24.9 [21.6 to 28.8]    | 0.957   |
| Follow-up duration (months)            | 21.5 [6.8 to 29.8]    | 23.0 [12.8 to 26.3]     | 23.0 [16.5 to 28.5]    | 0.800   |
| Last ASD D (mm)                        | 10.5 [6.5 to 12.2]    | 13.2 [11.8 to 14.9]     | 17.6 [14.6 to 19.3]    | <0.001  |
| Last indexed ASD D (mm/m$^2$)          | 15.3 [10.0 to 16.4]   | 19.5 [16.1 to 23.1]     | 22.8 [19.4 to 26.8]    | <0.001  |
| ASD D change (mm) during follow-up     | -3.1 [-6.8 to -1.5]   | -0.3 [-0.7 to 0.3]      | 2.7 [1.6 to 3.2]       | <0.001  |
| Indexed ASD D change (mm/m$^2$) during follow-up | -10.5 [-20.2 to -3.5] | -5.5 [-6.4 to -3.8] | -1.2 [-3.2 to 0.6] | <0.001  |
| Deficient aortic rim                    | 7 (77.8)              | 18 (46.2)               | 14 (35.9)              | 0.200   |
| Deficient posterior rim                 | 0 (0)                 | 5 (35.7)                | 9 (64.3)               | 0.006   |
| Deficient SVC rim                       | 0 (0)                 | 2 (66.7)                | 1 (33.3)               | 1.000   |
| Deficient IVC rim                       | 0 (0)                 | 1 (33.3)                | 2 (66.7)               | 0.579   |
| Deficient mitral rim                    | 0 (0)                 | 1 (33.3)                | 2 (66.7)               | 0.579   |
| Floppy IAS                              | 1 (33.3)              | 1 (33.3)                | 1 (33.3)               | 1.000   |

Values are median [25% to 75% range] or number (%).

Decreased group, patients with decreased ASD diameter; Stationary group, patients with unchanged ASD diameter (within ±1 mm); Increased group, patients with increased ASD diameter.

ASD = atrial septal defect; ASD D = atrial septal defect diameter; BSA = body surface area; IAS = interatrial septum; IVC = inferior vena cava; SVC = superior vena cava.
significant difference between the diuretic group and the non-diuretic groups (p=0.11 and p=0.06, respectively).

**Differences in the distribution of atrial septal defect treatment methods between the diuretic and non-diuretic groups**

Figure 4 shows the distribution of the ASD treatments both in the diuretic and non-diuretic groups. Significant differences were observed for the distribution of treatments methods between the groups (p=0.001). In the non-diuretic group, surgery was the most commonly used treatment method (n=18 [54.5%]) followed by device closure (n=13 [39.4%]). The ASD size did not decrease to an extent that would render treatment unnecessary in any of the patients, while two patients were lost to follow-up. Conversely, in the diuretic group, 30 patients (75%) underwent device closure which was the most commonly used treatment method followed by surgery (n=6 [15.0%]). ASD size was reduced to a range that rendered treatment unnecessary in two patients in the diuretic group. A 6-month-old male patient whose initial maximal ASD diameter was 13.5 mm showed a decreased ASD diameter of 3.1 mm following 4.1 years of diuretic use. Another patient, a 2.1-year-old male individual, showed an initial maximal ASD diameter of 11 mm; following 1.6 years of diuretic use, it was decreased to 6.4 mm. The other two patients in the diuretic group were lost to follow-up.
DISCUSSION

In this study, diuretic administration seemed to be associated with changes in ASD size in pediatric patients with a large secundum ASD. In addition, it may be associated with reducing the need for early surgical ASD closure and increasing the rate of transcatheter closure. To the best of our knowledge, no studies have focused on effect of diuretics on ASD size changes until now.

The success rate of transcatheter ASD closure is approximately 95%, with the feasibility and safety of the technique being previously established.\(^9\) The prevalence rate of complications is favorable, as it is 1% in the case of transcatheter ASD closure.\(^{11-13}\) Accordingly, transcatheter secundum ASD closure is preferred over surgery and is being attempted at a younger age;\(^{20-24}\) however, recent studies reported both lower periprocedural success rates and an increased risk of periprocedural and long-term complications with the use of transcatheter closure either when body weight is ≤15 kg or in the presence of a large secundum ASD (≥20 mm/ \(\text{m}^2\)).\(^{11,17}\) Therefore, for improved procedural success rates and reduced complication rates, it is reasonable to delay the procedure until the weight is approximately 15 kg.

In general, when the ASD diameter is ≥10 mm, it is known to cause a significant L-R shunt, resulting in RV volume overload.\(^3\) We used diuretics for RV volume unloading and expected to use a smaller sized device later through ASD size reduction. We hypothesized that the use of diuretics reduces preload and cause RA and RV volume unloading, thereby reducing the overall RA and RV dimensions and ASD diameter, thus making it possible to use a smaller device. In reality, as shown in Figure 3, the TV annulus z-score showed a significant difference over time between two groups according to the use of diuretics.

In our study, the ASD size was significantly reduced in the diuretic group compared with the non-diuretic group, and even two patients in the diuretic group showed an ASD size decrease to a level that rendered treatment unnecessary.\(^{19}\)

Diuretics are used to reduce preload in some patients with CHD.\(^{28}\) Although there are some concerns about hearing loss associated with the use of high doses of furosemide, recent studies have reported that furosemide and hearing loss are not significantly associated.\(^{21,24}\) There is still no clear evidence for complications from long-term use of oral diuretics in children and may be controversial. While concerns might exist regarding the long-term use of diuretics, there were no complications, including those regarding growth retardation at the diuretic dose within 1 mg/kg/day that we used.

We investigated the diuretic group by dividing it into three subgroups according to the response to diuretics (Table 3). In the three groups, clinical features did not show any significant difference, and only posterior rim deficiency showed a significant difference and did not have a chance of ASD diameter decrease. The characteristics of the three subgroups according to the ASD size change in the non-diuretic group are presented in Supplementary Table 1. We found that the ASD size was increased in all patients with posterior rim deficiency in the non-diuretic group. Moreover, all patients with IVC rim deficiency showed an increased ASD diameter in the non-diuretic group. In this study, ASD size reduction was not found in patients with posterior rim deficiency, even among those who received diuretics. Therefore, for patients with posterior rim deficiency, the use of diuretics is likely to be partially effective.
In addition, in our patient group, the number of patients with IVC rim deficiency was significantly higher in the non-diuretic group (7.5 vs. 42.4%, \( p=0.01 \)), and this difference in distribution of rim deficiency between two groups may have an effect on the difference in treatment trends. So, we investigated whether the distribution of treatment methods was different in the diuretic group and the non-diuretic group even within each subgroup with rim deficiency (Supplementary Table 2). Since the number of patients in each subgroup is small, there is a limit for analysis, however, when looking at patients with posterior rim deficiency, there was a significant difference in treatment distribution between the diuretic and the non-diuretic group (\( p=0.046 \)). In addition, while all patients with IVC rim deficiency in the non-diuretic group underwent surgery, one patient in the diuretic group was able to undergo successful device closure, although the number of patients was limited to evaluate it. However, there is still no clear explanation for the relationship between rim deficiency and diuretic effect. Nonetheless, as shown in our data, regardless of the diuretic use, there seemed to be a little possibility of ASD size reduction in case of rim deficiency other than the aortic rim.

Notably, in this study, the mean ASD diameter remained unchanged while the indexed ASD diameter in the diuretic group decreased significantly compared to that in the non-diuretic group. Therefore, in the non-diuretic group, the ASD size increased in accordance with the increase of body growth; However, the use of diuretics seemed to be associated with preventing an increase in the ASD size according to body growth.

While the effect of diuretics on reducing the ASD size and the resulting outcomes may vary across patients, our data showed that the patients in the diuretic and non-diuretic groups showed significantly different treatment distribution patterns (\( p=0.001 \), Figure 4). The patients with diuretics underwent more non-invasive treatments such as observation or device closure than surgical closure. In addition, even within the diuretic group, the distribution of treatment methods differed depending on whether the patients responded to diuretics (\( p=0.016 \), Supplementary Figure 1). In the group with a decreased ASD size following the use of diuretics, none of the patients underwent surgery. However, 5.6% and 35.7% of the patients in the stationary and the increased groups, respectively, underwent surgery. A patient’s response to diuretics positively correlated with the probability of transcatheter device closure than surgical closure.

We investigated patients who underwent surgery in both groups (Supplementary Table 3). If the ASD size was relatively large and had several rim deficiencies including posterior rim deficiency at the same time, surgical closure was performed more frequently. Though device closure could have been performed in some cases, the surgery was performed according to the preference of the physician or the request of the patients with the large ASDs with several rim deficiencies.

Interestingly, the weight and height growth rates over time did not show any significant difference in the two groups. Of course, it is premature to conclude that the growth rate was not retarded in the diuretic group only from our data, but at least the likelihood of developing specific side effects from diuretic use does not appear to be alarmingly high.

Our study has several limitations. Because of its retrospective design, the potential presence of various biases including selection bias cannot be completely excluded. We included patients with a follow-up period of approximately 6 months or longer, excluding those who were treated immediately after diagnosis, and the follow-up period was similarly matched in
both groups. However, it cannot be completely excluded that the consideration of the timing of treatment may have influenced the decision to take diuretics. Additionally, since the total number of patients and the number of patients in each subgroup were small, limitations exist regarding the evaluation of the effect of diuretics, which necessitates the need of randomized controlled trial to get more concrete evidence of the effect of diuretics on ASD size reduction; however, we observed statistically significant differences in the degree of ASD size reduction in diuretic compared to the non-diuretic group.

In pediatric patients with a large secundum ASD (diameter ≥10 mm), diuretic administration seems to be associated with changes in ASD size. The patients receiving diuretics may have a lower possibility to undergo surgical closure. The diuretics administration may be associated with the use of smaller ASD devices for transcatheter treatment through ASD size reduction.

SUPPLEMENTARY MATERIALS

Supplementary Table 1
Characteristics of each group according to atrial septal defect size change in the non-diuretic group

Click here to view

Supplementary Table 2
Distribution of atrial septal defect treatment according to the use of diuretics in each subgroup with rim deficiency

Click here to view

Supplementary Table 3
Patients who underwent surgery in the diuretic and non-diuretic groups

Click here to view

Supplementary Figure 1
Treatment distribution according to atrial septal defect size change in the diuretic group. The distribution of treatment methods significantly differed depending on the patients’ diuretic treatment response (p=0.016). The patients who did not respond to diuretics were more likely to eventually undergo surgery.

Click here to view

REFERENCES

1. Allen HD, Driscoll DJ, Shaddy RE, Feltes TF. Moss & Adams’ heart disease in infants, children, and adolescents: including the fetus and young adult. Philadelphia (PA): Lippincott Williams & Wilkins; 2013.

2. Baumgartner H, De Backer J, Babu-Narayan SV, et al. ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2020;41:4153-4.
3. Nyboe C, Olsen MS, Nielsen-Kudsk JE, Hjortdal VE. Atrial fibrillation and stroke in adult patients with atrial septal defect and the long-term effect of closure. *Heart* 2015;101:706-11.

4. Ooi YK, Kelleman M, Ehrlich A, et al. Transcatheter versus surgical closure of atrial septal defects in children: a value comparison. *JACC Cardiovasc Interv* 2016;9:79-86.

5. Butera G, Biondi-Zoccai G, Sangiorgi G, et al. Percutaneous versus surgical closure of secundum atrial septal defects: a systematic review and meta-analysis of currently available clinical evidence. *Europace* 2011;13:377-85.

6. Rao PS, Harris AD. Recent advances in managing septal defects: atrial septal defects. *F1000 Res* 2017;6:2042.

7. Kim JH, Yun S, Hwang SS, et al. The 2017 Korean National Growth Charts for children and adolescents: development, improvement, and prospects. *Korean J Pediatr* 2018;61:135-49.

8. Pettersen MD, Du W, Skeens ME, Humes RA. Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. *J Am Soc Echocardiogr* 2008;21:922-34.

9. Losay J, Petit J, Lambert V, et al. Percutaneous closure with Amplatzer device is a safe and efficient alternative to surgery in adults with large atrial septal defects. *Am Heart J* 2001;142:544-8.

10. Masura J, Gavora P, Podnar T. Long-term outcome of transcatheter secundum-type atrial septal defect closure using Amplatzer septal occluders. *J Am Coll Cardiol* 2005;45:505-7.

11. Jalal Z, Hascoët S, Gronier C, et al. Long-term outcomes after percutaneous closure of ostium secundum atrial septal defect in the young: a nationwide cohort study. *JACC Cardiovasc Interv* 2018;11:795-804.

12. Jung SY, Kim AY, Jung JW, Choi JY. Procedural, early and long-term outcomes after percutaneous closure of atrial septal defect: comparison between large and very large atrial septal defect groups. *Korean Circ J* 2019;49:975-86.

13. De Wolf D. Complications of transcatheter atrial septal defect closure. *Interact Cardiol (Lond)* 2009;1:209-18.

14. Petit CJ, Justino H, Pignatelli RH, Crystal MA, Payne WA, Ing FF. Percutaneous atrial septal defect closure in infants and toddlers: predictors of success. *Pediatr Cardiol* 2013;34:220-5.

15. Saritas T, Yucel IK, Demir IH, Demir F, Erdem A, Celebi A. Comparison of transcatheter atrial septal defect closure in children, adolescents and adults: differences, challenges and short-, mid- and long-term results. *Korean Circ J* 2016;46:851-61.

16. Butera G, De Rosa G, Chessa M, et al. Transcatheter closure of atrial septal defect in young children: results and follow-up. *J Am Coll Cardiol* 2003;42:241-5.

17. Bartakian S, Fagan TE, Schaffer MS, Darst JR. Device closure of secundum atrial septal defects in children <15 kg: complication rates and indications for referral. *JACC Cardiovasc Interv* 2012;5:1178-84.

18. Tanghøj G, Odermarsky M, Naumburg E, Liuba P. Early complications after percutaneous closure of atrial septal defect in infants with procedural weight less than 15 kg. *Pediatr Cardiol* 2017;38:255-63.

19. Brassard M, Fouron JC, van Doesburg NH, Mercier LA, De Guise P. Outcome of children with atrial septal defect considered too small for surgical closure. *Am J Cardiol* 1999;83:1552-5.

20. Hsu DT, Pearson GD. Heart failure in children: part II: diagnosis, treatment, and future directions. *Circ Heart Fail* 2009;2:490-8.

21. Ding D, Liu H, Qi W, et al. Ototoxic effects and mechanisms of loop diuretics. *J Otol* 2016;11:145-56.
22. Lin BM, Curhan SG, Wang M, Eavey R, Stankovic KM, Curhan GC. Hypertension, diuretic use, and risk of hearing loss. Am J Med 2016;129:416-22. PUBMED | CROSSREF

23. Jackson W, Taylor G, Selewski D, Smith PB, Tolleson-Rinehart S, Laughon MM. Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review. Matern Health Neonatol Perinatol 2018;4:23. PUBMED | CROSSREF

24. Wang LA, Smith PB, Laughon M, et al. Prolonged furosemide exposure and risk of abnormal newborn hearing screen in premature infants. Early Hum Dev 2018;125:26-30. PUBMED | CROSSREF